NCT06363370View on ClinicalTrials.gov

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

PHASE3RecruitingINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Human interferon α1b Inhalation Solution

Participants will receive Human interferon α1b Inhalation Solution

DRUG

Inhalation Solution Placebo

Participants will receive Inhalation Solution Placebo

Trial Locations (1)

100000

RECRUITING

Children's Hospital, Capital Institute of Pediatrics, Beijing

Sponsors
All Listed Sponsors
lead

Kexing Biopharm Co., Ltd.

INDUSTRY

NCT06363370 - Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | Biotech Hunter | Biotech Hunter